- Home
- TGB vs EYPT Comparison
TGB vs EYPT Comparison
Compare TGB & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGB
- EYPT
- Stock Information
- Founded
- TGB 1966
- EYPT 1987
- Country
- TGB Canada
- EYPT United States
- Employees
- TGB N/A
- EYPT N/A
- Industry
- TGB Precious Metals
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- TGB Basic Materials
- EYPT Industrials
- Exchange
- TGB Nasdaq
- EYPT Nasdaq
- Market Cap
- TGB 698.1M
- EYPT 579.4M
- IPO Year
- TGB N/A
- EYPT 2005
- Fundamental
- Price
- TGB $3.62
- EYPT $10.36
- Analyst Decision
- TGB
- EYPT Strong Buy
- Analyst Count
- TGB 0
- EYPT 8
- Target Price
- TGB N/A
- EYPT $24.75
- AVG Volume (30 Days)
- TGB 11.5M
- EYPT 838.1K
- Earning Date
- TGB 07-30-2025
- EYPT 08-06-2025
- Dividend Yield
- TGB N/A
- EYPT N/A
- EPS Growth
- TGB N/A
- EYPT N/A
- EPS
- TGB N/A
- EYPT N/A
- Revenue
- TGB $417,640,101.00
- EYPT $56,042,000.00
- Revenue This Year
- TGB $22.13
- EYPT N/A
- Revenue Next Year
- TGB $36.13
- EYPT N/A
- P/E Ratio
- TGB N/A
- EYPT N/A
- Revenue Growth
- TGB 7.89
- EYPT 12.04
- 52 Week Low
- TGB $1.67
- EYPT $3.91
- 52 Week High
- TGB $3.68
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- TGB 71.05
- EYPT 61.63
- Support Level
- TGB $3.15
- EYPT $9.45
- Resistance Level
- TGB $3.68
- EYPT $11.69
- Average True Range (ATR)
- TGB 0.18
- EYPT 0.83
- MACD
- TGB 0.03
- EYPT 0.03
- Stochastic Oscillator
- TGB 90.66
- EYPT 64.53
About TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.